Adaptive CDMO Biologic Manufacturing: The Era Beyond Platforms Biologic programs don’t all behave like monoclonal antibodies—and pretending they do costs time and money. This piece lays out a practical alternative: adaptive CDMO biologic manufacturing. In plain terms, it’s a way of working that matches the process to the molecule, not the other way around. It […]
Tag: cytotoxicity
Stop Wasting Runs: Your E. coli CDMO Guide—Now
If you’re evaluating E. coli CDMO services, you already know the chassis is unmatched for speed, cost control, and sheer engineering leverage. The difference between programs that glide to GMP and programs that grind through deviations isn’t a single hack; it’s a governed stack that turns biology into an instrumented process. Start with host architecture […]
13 Contamination Traps in Animal Health CDMO—Catch Them Before They Bite
13 Contamination Traps in Animal Health CDMO – Introduction Contamination doesn’t announce itself; it drifts in as a “minor deviation” and leaves you with failed release, blown timelines, or a recall. Animal health programs are uniquely exposed: probiotics and sterile injectables under one roof, waterline dosing in barns and hatcheries, larger IV bags, and species […]
The Future of Fusion Biologics: Fc, Albumin, Minibodies & Beyond
Introduction: Why Fusion Matters Biologics are entering a new era—one not defined solely by monoclonal antibodies but by engineered fusion constructs. The antibody was the great engine of the last two decades, dominating pipelines across oncology, autoimmunity, and rare disease. But today, as pipelines diversify, the limitations of conventional antibodies are increasingly clear. Fusion proteins—Fc-fusions, […]
The Convergence of AI and Biopharma Data Analysis
As we delve into the recent innovations at the intersection of artificial intelligence (AI) and biopharmaceutical data analysis, it is evident that the synergy between these fields is not merely additive but transformative. The application of AI in biopharma encompasses a range of complex, data-intensive challenges, from drug discovery and development to predictive modeling and […]